Takeda

FDA grants priority review for Takeda and HUTCHMED’s fruquintinib NDA
FDA grants priority review for Takeda and HUTCHMED’s fruquintinib NDA
Pharmaceutical Technology
Takeda
Hutchmed
FDA
fruquintinib
colorectal cancer
Flag link:
Takeda puts $510M on the line to expand KSQ cancer collaboration
Takeda puts $510M on the line to expand KSQ cancer collaboration
Fierce Biotech
Takeda
KSQ Therapeutics
cancer
oncology
Flag link:
Big Pharma layoffs: BMS, Roche and Takeda axe hundreds of jobs
Big Pharma layoffs: BMS, Roche and Takeda axe hundreds of jobs
Medical Marketing and Media
layoffs
Bristol Myers Squibb
Roche
Takeda
Gossamer Bio
Novavax
Flag link:
Takeda cuts 2 midstage GI assets including Crohn's hopeful in latest pipeline cleanup
Takeda cuts 2 midstage GI assets including Crohn's hopeful in latest pipeline cleanup
Fierce Biotech
Takeda
R&D
gene therapy
earnings
Crohn’s disease
Flag link:
Gout Disease Control Suffered After FDA-Driven Price Hike: Study
Gout Disease Control Suffered After FDA-Driven Price Hike: Study
BioSpace
FDA
gout
colchicine
drug pricing
Takeda
Colcrys
Flag link:
Takeda Cuts 180+ Jobs Amid Pipeline Shake-Up
Takeda Cuts 180+ Jobs Amid Pipeline Shake-Up
BioSpace
Takeda
layoffs
Massachusetts
Flag link:
Takeda tries again with subcutaneous Entyvio
Takeda tries again with subcutaneous Entyvio
Pharmaphorum
Takeda
Entyvio
ulcerative colitis
Flag link:
Takeda taps Innate for a new celiac approach
Takeda taps Innate for a new celiac approach
EP Vantage
Takeda
celiac disease
Innate Pharma
antibody-drug conjugate
Flag link:
Takeda hit with another pay-for-delay lawsuit, this time on gout drug Colcrys
Takeda hit with another pay-for-delay lawsuit, this time on gout drug Colcrys
Fierce Pharma
Takeda
pay-for-delay
generics
gout
Colcrys
Flag link:
Layoffs loom as Takeda trims early-stage efforts in AAV gene therapy, rare hematology
Layoffs loom as Takeda trims early-stage efforts in AAV gene therapy, rare hematology
Fierce Biotech
Takeda
R&D
gene therapy
hematology
Flag link:
Takeda opens 4th front in assault on celiac, tapping Innate to develop antibody-drug conjugates
Takeda opens 4th front in assault on celiac, tapping Innate to develop antibody-drug conjugates
Fierce Biotech
Takeda
celiac disease
antibody-drug conjugate
Innate Pharma
Flag link:
Go or no go? Seagen's Padcev eyes FDA approval
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Flag link:
Takeda invests $760M+ into new plasma-derived therapy manufacturing site in Japan
Takeda invests $760M+ into new plasma-derived therapy manufacturing site in Japan
Endpoints
Takeda
Japan
plasma therapy
drug manufacturing
Flag link:
Takeda, chasing Bristol Myers, unveils awaited TYK2 drug data
Takeda, chasing Bristol Myers, unveils awaited TYK2 drug data
BioPharma Dive
Takeda
Bristol Myers Squibb
clinical trials
TAK-279
plaque psoriasis
Flag link:
Takeda’s Vedolizumab Clears Phase III in aGvHD
Takeda’s Vedolizumab Clears Phase III in aGvHD
BioSpace
Takeda
vedolizumab
graft vs host disease
clinical trials
Flag link:
Takeda's Iclusig shows potential to become standard of care in acute lymphoblastic leukemia subtype
Takeda's Iclusig shows potential to become standard of care in acute lymphoblastic leukemia subtype
Fierce Pharma
Takeda
Iclusig
acute lymphoblastic leukemia
ALL
ASCO
Flag link:
Japan cancels 140M dose order for Novavax Covid vaccine amid 'lower than expected' demand
Japan cancels 140M dose order for Novavax Covid vaccine amid 'lower than expected' demand
Endpoints
Japan
Novavax
COVID-19
vaccines
Takeda
Flag link:
Takeda focuses on ‘diverse’ pipeline prospects on heels of two acquisitions
Takeda focuses on ‘diverse’ pipeline prospects on heels of two acquisitions
Endpoints
Takeda
Nimbus Therapeutics
Hutchmed
colorectal cancer
psoriasis
fruquintinib
Flag link:
Q4 earnings roundup: Merck, Lilly, Takeda and BMS release financials
Q4 earnings roundup: Merck, Lilly, Takeda and BMS release financials
Medical Marketing and Media
earnings
Merck
Takeda
Bristol Myers Squibb
Eli Lilly
Flag link:
The world's twelfth VEGF drug will be sold by Takeda
The world's twelfth VEGF drug will be sold by Takeda
EP Vantage
Takeda
Hutchmed
VEGF
fruquintinib
Flag link:

Pages